In vitro susceptibility of Burkholderia vietnamiensis to aminoglycosides

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2256-2264

  Jassem, Agatha N ^a   Zlosnik, James E A ^a   Henry, Deborah A ^a   Hancock, Robert E W ^a   Ernst, Robert K ^b   Speert, David P ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZITHROMYCIN; CATHELICIDIN; GENTAMICIN; HABEKACIN; LIPOPOLYSACCHARIDE; POLYMYXIN B; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BURKHOLDERIA; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA VIETNAMIENSIS; EFFUSION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BURKHOLDERIA; GENTAMICINS; MASS SPECTROMETRY; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B;

EID: 79955537878     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01434-10     Document Type: Article

References (57)

1. Albrecht, M. T., W. Wang, O. Shamova, R. I. Lehrer, and N. L. Schiller. 2002. Binding of protegrin-1 to Pseudomonas aeruginosa and Burkholderia cepacia. Respir. Res. 3:18.
2. Avgeri, S. G., D. K. Matthaiou, G. Dimopoulos, A. P. Grammatikos, and M. E. Falagas. 2009. Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. Int. J. Antimicrob. Agents 33:394-404.
3. Baird, R. M., H. Brown, A. W. Smith, and M. L. Watson. 1999. Burkholderia cepacia is resistant to the antimicrobial activity of airway epithelial cells. Immunopharmacology 44:267-272.
4. Bryan, L. E., and H. M. Van den Elzen. 1976. Streptomycin accumulation in susceptible and resistant strains of Escherichia coli and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 9:928-938.
5. Buroni, S., et al. 2009. Assessment of three resistance-nodulation-cell division drug efflux transporters of Burkholderia cenocepacia in intrinsic antibiotic resistance. BMC Microbiol. 9:200.
6. Caroff, M., A. Tacken, and L. Szabo. 1988. Detergent-accelerated hydrolysis of bacterial endotoxins and determination of the anomeric configuration of the glycosyl phosphate present in the "isolated lipid A" fragment of the Bordetella pertussis endotoxin. Carbohydr. Res. 175:273-282.
7. Chu, K. K. 2004. Ph.D. thesis. University of British Columbia, Vancouver, British Columbia, Canada.
8. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M07-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Corey, M., and V. Farewell. 1996. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am. J. Epidemiol. 143:1007-1017.
10. De Soyza, A., A. Silipo, R. Lanzetta, J. R. Govan, and A. Molinaro. 2008. Chemical and biological features of Burkholderia cepacia complex lipopolysaccharides. Innate Immun. 14:127-144.
11. Dubarry, N., W. Du, D. Lane, and F. Pasta. 2010. Improved electrotransformation and decreased antibiotic resistance of the cystic fibrosis pathogen Burkholderia cenocepacia strain J2315. Appl. Environ. Microbiol. 76:1095-1102.
12. Emerson, J., S. McNamara, A. M. Buccat, K. Worrell, and J. L. Burns. 2010. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr. Pulmonol. 45:363-370.
13. Ernst, R. K., et al. 2007. Unique lipid A modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis. J. Infect. Dis. 196:1088-1092.
14. Fernandez, L., et al. 2010. Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS. Antimicrob. Agents Chemother. 54:3372-3382.
15. Flume, P. A., et al. 2007. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 176:957-969.
16. Hamad, M. A., A. M. Skeldon, and M. A. Valvano. 2010. Construction of aminoglycoside-sensitive Burkholderia cenocepacia strains for studying intracellular bacteria by the gentamicin protection assay. Appl. Environ. Microbiol. 76:3170-3176.
17. Hancock, R. E. W. 1981. Aminoglycoside uptake and mode of action - with special reference to streptomycin and gentamicin. I. Antagonists and mutants. J. Antimicrob. Chemother. 8:249-276.
18. Hancock, R. E. W. 1981. Aminoglycoside uptake and mode of action - with special reference to streptomycin and gentamicin. II. Effects of aminoglycosides on cells. J. Antimicrob. Chemother. 8:429-445.
19. Hancock, R. E. W. 1997. Peptide antibiotics. Lancet 349:418-422. (Pubitemid 27077684)
20. Hancock, R. E. W., and H. G. Sahl. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557.
21. Hirschfeld, M., Y. Ma, J. H. Weis, S. N. Vogel, and J. J. Weis. 2000. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J. Immunol. 165:618-622.
22. Hitchcock, P. J., and T. M. Brown. 1983. Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J. Bacteriol. 154:269-277.
23. Ierano, T., et al. 2010. The lipid A of Burkholderia multivorans C1576 smooth-type lipopolysaccharide and its pro-inflammatory activity in a cystic fibrosis airways model. Innate Immun. 16:354-365.
24. Ierano, T., et al. 2008. The structure and proinflammatory activity of the lipopolysaccharide from Burkholderia multivorans and the differences between clonal strains colonizing pre- and posttransplanted lungs. Glycobiology 18:871-881.
25. Ierano, T., et al. 2009. First structural characterization of Burkholderia vietnamiensis lipooligosaccharide from cystic fibrosis-associated lung transplantation strains. Glycobiology 19:1214-1223.
26. Isles, A., et al. 1984. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J. Pediatr. 104:206-210. (Pubitemid 14188925)
27. Jassem, A. N., J. E. A. Zlosnik, D. A. Henry, R. K. Ernst, and D. P. Speert. 2010. In vitro susceptibility of Burkholderia vietnamiensis to aminoglycosides, abstr. 389. Abstr. 24th N. Am. Cyst. Fibros. Conf., Baltimore, MD.
28. Jassem, A. N., J. E. A. Zlosnik, R. K. Ernst, R. E. W. Hancock, and D. P. Speert. 2009. Outer membrane mediated aminoglycoside resistance in the Burkholderia cepacia complex, abstr. C1-092. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA. American Society for Microbiology, Washington, DC.
29. Jeannot, K., M. L. Sobel, F. El Garch, K. Poole, and P. Plesiat. 2005. Induction of the MexXY efflux pump in Pseudomonas aeruginosa is dependent on drug-ribosome interaction. J. Bacteriol. 187:5341-5346. (Pubitemid 41022953)
30. Kwon, D. H., and C. D. Lu. 2006. Polyamines induce resistance to cationic peptide, aminoglycoside, and quinolone antibiotics in Pseudomonas aeruginosa PAO1. Antimicrob. Agents Chemother. 50:1615-1622.
31. Loh, B., C. Grant, and R. E. W. Hancock. 1984. Use of the fluorescent probe 1-N-phenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 26:546-551.
32. Lomovskaya, O. 2009. Efflux pump inhibitors: a promising therapeutic strategy, abstr. 1804. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA. American Society for Microbiology, Washington, DC.
33. Loutet, S. A., S. J. Bartholdson, J. R. W. Govan, D. J. Campopiano, and M. A. Valvano. 2009. Contributions of two UDP-glucose dehydrogenases to viability and polymyxin B resistance of Burkholderia cenocepacia. Microbiology 155:2029-2039.
34. Loutet, S. A., R. S. Flannagan, C. Kooi, P. A. Sokol, and M. A. Valvano. 2006. A complete lipopolysaccharide inner core oligosaccharide is required for resistance of Burkholderia cenocepacia to antimicrobial peptides and bacterial survival in vivo. J. Bacteriol. 188:2073-2080.
35. Mahenthiralingam, E., et al. 2000. Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J. Clin. Microbiol. 38:910-913.
36. Mahenthiralingam, E., T. A. Urban, and J. B. Goldberg. 2005. The multifarious, multireplicon Burkholderia cepacia complex. Nat. Rev. Microbiol. 3:144-156.
37. Masuda, N., et al. 2000. Contribution of the MexX-MexY-OprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:2242-2246.
38. Moore, R. A., and R. E. W. Hancock. 1986. Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrob. Agents Chemother. 30:923-926.
39. Nzula, S., P. Vandamme, and J. R. W. Govan. 2002. Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. J. Antimicrob. Chemother. 50:265-269.
40. Ortega, X. P., et al. 2007. A putative gene cluster for aminoarabinose biosynthesis is essential for Burkholderia cenocepacia viability. J. Bacteriol. 189:3639-3644. (Pubitemid 46668829)
41. Peeters, E., H. J. Nelis, and T. Coenye. 2009. In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria. J. Antimicrob. Chemother. 64:801-809.
42. Poole, K. 2005. Efflux-mediated antimicrobial resistance. J. Antimicrob. Chemother. 56:20-51.
43. Raetz, C. R. H., C. M. Reynolds, M. S. Trent, and R. E. Bishop. 2007. Lipid A modification systems in gram-negative bacteria. Annu. Rev. Biochem. 76:295-329.
44. Schurek, K. N., et al. 2008. Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52:4213-4219.
45. Schwab, U., P. Gilligan, J. Jaynes, and D. Henke. 1999. In vitro activities of designed antimicrobial peptides against multidrug-resistant cystic fibrosis pathogens. Antimicrob. Agents Chemother. 43:1435-1440.
46. Speert, D. P., M. Bond, R. C. Woodman, and J. T. Curnutte. 1994. Infection with Pseudomonas cepacia in chronic granulomatous disease: role of nonoxidative killing by neutrophils in host defense. J. Infect. Dis. 170:1524-1531.
47. Speert, D. P., D. Henry, P. Vandamme, M. Corey, and E. Mahenthiralingam. 2002. Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg. Infect. Dis. 8:181-187.
48. Trunck, L. A., et al. 2009. Molecular basis of rare aminoglycoside susceptibility and pathogenesis of Burkholderia pseudomallei clinical isolates from Thailand. PLoS Negl. Trop. Dis. 3:e519.
49. Turner, J., Y. Cho, N. N. Dinh, A. J. Waring, and R. I. Lehrer. 1998. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob. Agents Chemother. 42:2206-2214.
50. Vanlaere, E., et al. 2009. Taxon K, a complex within the Burkholderia cepacia complex, comprises at least two novel species, Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov. Int. J. Syst. Evol. Microbiol. 59:102-111.
51. Vanlaere, E., et al. 2008. Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov. and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex. Int. J. Syst. Evol. Microbiol. 58:1580-1590.
52. Vermis, K., P. A. R. Vandamme, and H. J. Nelis. 2003. Burkholderia cepacia complex genomovars: utilization of carbon sources, susceptibility to antimicrobial agents and growth on selective media. J. Appl. Microbiol. 95:1191-1199.
53. Westphal, O., and K. Jann. 1965. Bacterial lipopolysaccharides: extraction with phenol-water and further applications of the procedure. Methods Carbohydr. Chem. 5:83-91.
54. Wu, M., and R. E. W. Hancock. 1999. Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. J. Biol. Chem. 274:29-35.
55. Yi, E. C., and M. Hackett. 2000. Rapid isolation method for lipopolysaccharide and lipid A from gram-negative bacteria. Analyst 125:651-656.
56. Zhang, L., et al. 2005. Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob. Agents Chemother. 49:2921-2927.
57. Zlosnik, J. E. A., et al. 2011. Mucoid and nonmucoid Burkholderia cepacia complex bacteria in cystic fibrosis infections. Am. J. Respir. Crit. Care Med. 183:67-72.